Now a three-time loser, selumetinib continues to cause headaches as AstraZeneca dumps a failed PhIII
Selumetinib continues to cause big headaches at AstraZeneca $AZN.
The MEK inhibitor — now partnered with Merck $MRK in their big $8.5 billion alliance — failed a Phase III study for differentiated thyroid cancer, according to the Q2 report from AstraZeneca. And they quietly whisked that program out of the pipeline in a virtual footnote to its quarterly report.
The failure makes this drug a three-time loser, though it’s still in clinical trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
